VIVUS, Nordmark revise contract agreement for PANCREAZE development
Category: #health  By Pankaj Singh  Date: 2019-06-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

VIVUS, Nordmark revise contract agreement for PANCREAZE development

California-headquartered biopharmaceutical firm VIVUS Inc. has recently announced an amendment to its contract manufacturing and supply agreement of delayed release capsules PANCREAZE® with Nordmark Arzneimittel GmbH & Co. KG.

Apparently, the revised treaty covers an initial term of 10 years followed by a renewal of additional five years. Financial terms of the agreement remained undisclosed.

Citing reliable sources, VIVUS and Nordmark will work together under the terms of the agreement to develop an advanced formulation of PANCREAZE, which is expected to enter the market by 2021, with the prime goal of extending its shelf life.

John Amos, Chief Executive Officer, VIVUS, was quoted saying that ensuring the supply of PANCREAZE to meet current and future demands of the drug at a predictable and stable price was their key strategy. He further added that with their current product formulations, there lies a bright future for PACREAZE market to create additional commercial and clinical value with the introduction of the product’s advanced formulations.

Nordmark CEO Jörn Tonne stated that their firm has managed to achieve considerable expertise in manufacturing PANCREAZE, and they look forward to extending their agreement with VIVUS. He also mentioned that they have had a successful record in developing new products to meet customer needs as well as the patients they serve.

Tonne noted that Nordmark plans to work with VIVUS in developing advanced formulations of PANCREAZE that make the drug even more convenient for patients diagnosed with exocrine pancreatic insufficiency.

For the record, PANCREAZE is a prescription drug used for treatment of patients who have difficulty digesting food normally because their pancreas, due to cystic fibrosis or other conditions, is unable to produce enough enzymes. PANCREAZE contains a mixture of digestive enzymes including amylases, proteases and lipases from pig pancreas, that helps body use up proteins, sugars and fats from food. The drug is effective and completely safe in children when taken in prescribed doses.

 

Source credit: https://www.nasdaq.com/press-release/vivus-and-nordmark-amend-contract-manufacturing-agreement-to-supply-current-and-future-demand-for-20190626-00835



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...